Obalon Therapeutics Inc
OBLN
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.47M
Close$
$3.55
16.5% upside
Current Fair Value
16.5% upsideUndervalued by 16.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.47 Million |
|---|---|
| Enterprise Value | $-2,397,890.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $0 |
| Beta | -1.24 |
| Outstanding Shares | 7,018,528 |
Return
| Return on Equity | -133.73% |
|---|---|
| Return on Assets | -106.56% |
| Return on Invested Capital | -136.45% |
Valuation & Multiples
| P/E Ratio | 9.53 |
|---|---|
| PEG | -12.89 |
| Price to Sales | -3.05 |
| Price to Book Ratio | 3.05 |
| Enterprise Value to Revenue | 1.21 |
| Enterprise Value to EBIT | 0.24 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.01 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Obalon Therapeutics Inc
CEO: Andrew Rasdal